SOURCE: Pacific Dynasty Consultants / Issues Investment Alert On (NASDAQ: GIVN), (NASDAQ: BODY), (NASDAQ: LULU), (NASDAQ: TELK), (NYSE: SAP) Is announcing Investment Highlights on Given Imaging Ltd. (NASDAQ: GIVN), Body Central Corp (NASDAQ: BODY), Lululemon Athletica inc. (NASDAQ: LULU)

Pompano Beach, FL, January 15, 2013 -- Given Imaging Ltd. (NASDAQ: GIVN) shares fell 11.65% to $16.08 in the early hour after the company said it is ending its previously announced exploration of a possible sale or merger transaction as part of its evaluation of strategic options in order to maximize growth and enhance shareholder value. According to the executive committee of the Board of Directors appointed to oversee the process, the continued execution of the company's operating plan, supplemented by additional acquisitions and alliances, provides the best opportunity at this time to enhance value for all of its shareholders.

Will GIVN Move Higher After Today’s Sudden Selling Activities? Don’t Miss The Free Trend Analysis here 

Body Central Corp (NASDAQ: BODY) shares declined 13.08% to $8.44. The company is using Avery Dennison's Pathfinder(R) markdown solution to increase margins and help enhance the customer experience by improving markdown accuracy.

Additionally, the company announced sales results for the fourth quarter and fiscal year ended December 29, 2012 and lowered guidance for fourth quarter 2012 results. Net revenues for the quarter increased 0.4% to $81.0 million, compared to $80.7 million for the fourth quarter of 2011.

How Should Investors Trade BODY After The Recent Momentum, Find Out Here

Lululemon Athletica inc. (NASDAQ: LULU) stock dropped 7.43% to $ 67.01 after the company announced that it now anticipates fourth quarter revenue will be at the high end of its original guidance range of $475 million to $480 million. The Company now expects diluted EPS will be $0.74, compared to previous guidance of 0.71 to $0.73.

Get Free Special Trend Analysis On LULU Here 

Telik, Inc. (NASDAQ: TELK) shares dropped 11.12% and closed at $2. The company, on Jan. 11, said that it was notified that its product candidate, ezatiostat HCL (Telintra), has been granted orphan drug designation by the US Food and Drug Administration (FDA) for the treatment of myelodysplastic syndrome (MDS).  Orphan designation grants potential US market exclusivity to a drug for the treatment of a specified condition for a period of seven years following FDA marketing approval.

Get Free Special Trend Analysis On TELK Here 

SAP AG (ADR) (NYSE: SAP) stock gained 0.12% to $81.88 after the company disclosed preliminary results for the fourth quarter that disappointed the Street. For the quarter, total revenue on a non-IFRS basis was 5.06 billion Euros, up 12% from a year ago, or 11% in constant currency. Street consensus was for 5.12 billion. Operating profit was 1.96 billion Euros, up 10%, or 9% in constant currency, and a little below consensus at 2 billion.

Get Free Special Trend Analysis On SAP Here 

About has a finger on the pulse of many sectors including renewable energy, oil, pharma, mining, finance, and healthcare. Our in depth research and analysis of NASDAQ, OTCBB, Pink Sheets, and NYSE has yielded considerable gains for our subscribers.

Our to-the-minute reports and alerts coupled with breaking news, analysis, investment strategies, and FREE subscription email services contribute to our role as one of the leading investor relations marketing firms.


The assembled information disseminated by is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. does expect that investors will buy and sell securities based on information assembled and presented in PLEASE always do your own due diligence, and consult your financial advisor.


Pacific Dynasty Consultants Inc.

2637 E Atlantic Blvd #22611 Pompano Beach, FL 33062